指南与共识泌尿生殖技术与安全MRPETCT

EAU-EANM-ESTRO-ESUR-SIOG前列腺癌指南-2020更新版第一部分:筛查、诊断与根治性局部治疗

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
指南 / 共识 · Eur Urol · 2020-11-07

该指南由EAU联合EANM、ESTRO、ESUR、SIOG制定,基于2016至2020年文献系统综述更新前列腺癌筛查、诊断与局部治疗推荐,并为每条推荐增加证据强度评级。推荐采用风险适应筛查策略、多参数磁共振成像以避免不必要活检、靶向联合系统活检,并对中危患者强烈推荐考虑中度大分割放疗。

要点

  • 推荐使用多参数磁共振成像以避免不必要的前列腺穿刺活检。
  • 进行活检时,必须提供靶向穿刺联合系统穿刺。
  • 低危患者及部分ISUP 2有利中危患者应始终讨论主动监测。

核心结论

  • 2020版EAU-EANM-ESTRO-ESUR-SIOG指南总结了前列腺癌筛查、诊断与根治性局部治疗的最新证据与临床实践建议,体现多学科管理性质。

研究设计与样本

  • 由欧洲泌尿外科学会(EAU)、欧洲核医学协会(EANM)、欧洲放射治疗与肿瘤学会(ESTRO)、欧洲泌尿生殖放射学会(ESUR)及国际老年肿瘤学会(SIOG)联合制定的指南,基于2016年至2020年文献综述更新,并对每条推荐增加基于系统证据综述的强度评级。

诊断标准与关键数值

  • 推荐对可能发生前列腺癌的男性采用风险适应策略,一般从50岁开始并基于个体化预期寿命。
  • 对风险增高的男性应从45岁开始提供风险适应筛查;对乳腺癌易感基因(BRCA)突变携带者(已证实存在早发和侵袭性疾病风险,主要为BRCA2)应从约40岁开始筛查。
  • 推荐使用多参数磁共振成像以避免不必要的活检;进行活检时,必须提供靶向穿刺联合系统穿刺。
  • 目前没有常规使用组织生物标志物的位置。
  • 前列腺特异性膜抗原正电子发射断层扫描计算机断层扫描是最灵敏的分期检查,但缺乏结局获益仍是主要局限。

临床应用与阅片要点

  • 对风险增高的男性及BRCA突变携带者应按相应年龄起点提供风险适应筛查。
  • 使用多参数磁共振成像以避免不必要的活检,活检时提供靶向联合系统穿刺。
  • 低危及部分ISUP 2有利中危患者应始终讨论主动监测。
  • 中危患者强烈推荐考虑中度大分割放疗;cN1期患者应接受局部治疗联合长期激素治疗。
  • 患者必须充分了解所有相关选择,并与治疗医师共同决定最适合的管理方案。

局限性

  • 前列腺特异性膜抗原正电子发射断层扫描计算机断层扫描虽为最灵敏的分期检查,但缺乏结局获益仍是主要局限。
  • 某些情况下新治疗方案的 supporting evidence 尚不够强,不足以提供推荐,因此需要持续更新。
  • 原文指出新见解需定期考虑并纳入指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).

EVIDENCE ACQUISITION: The panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.

EVIDENCE SYNTHESIS: A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.

CONCLUSIONS: The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.

PATIENT SUMMARY: Updated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020. PMID: 33172724. doi:10.1016/j.eururo.2020.09.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。